Enlivex Therapeutics Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K report covers the month of February 2026 for Enlivex Therapeutics Ltd., an Israeli company. The filing documents the results of an Extraordinary General Meeting of Shareholders held on February 3, 2026.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a corporate governance filing and does not contain financial statements.
Material Changes
Shareholders voted to approve amendments to the Company's Articles of Association. These amendments were previously described in the Notice and Proxy Statement filed on December 18, 2025. The approved amendments are now incorporated into the Company's Articles of Association.
Guidance, Outlook, and Risks
The filing does not contain management commentary on financial guidance, future outlook, specific risks, contingencies, or unusual items. The document focuses solely on the ratification of corporate governance changes.
Key Facts for Investors
- Shareholders approved amendments to the Articles of Association on February 3, 2026.
- The complete text of the amended Articles of Association is included as Exhibit 99.1.
- This information is incorporated by reference into the Company's active registration statements on Forms S-8, F-3, and F-3MEF.
- No financial performance data is disclosed in this specific filing.